The Boat Races will now be known as The Cancer Research UK Boat Races.
The Boat Races will now be known as The Cancer Research UK Boat Races.
CRUK's approach to scientific progress and medical breakthroughs is an inspiration to us. We are proud to be supported by them and hope that we can support the work they do as much as we can.
Cath Bishop, Chair of Cambridge University Women’s Boat Club
In a world first, BNY Mellon and Newton Investment Management, sponsors of The Boat Races, announced they are donating their title sponsorship of the annual challenge between Cambridge and Oxford Universities to Cancer Research UK (CRUK), the official charity partner.
The campaign will see Cancer Research UK receive substantial exposure throughout the Races, which will take place on the Championship Course on the River Thames between Putney and Mortlake on 27 March.
BNY Mellon and Newton Investment Management will work together with Cancer Research UK to support their fundraising activities in the build up to The Boat Races and will also be implementing their own initiatives with all fundraising in aid of Cancer Research UK.
Cath Bishop, Chair of Cambridge University Women’s Boat Club (CUWBC) said: “I know we are all really excited to be working closely alongside Newton Investment and Cancer Research UK as our Boat Race partners.
“Both organisations are dedicated to excellence, and CRUK is a cause close to all our hearts, so we are delighted that BNYM and Newton have decided to make their partnership with CRUK as close as it could be by donating the title rights to them.
“We will be proud to race with Cancer Research UK on our vests alongside the continuing fantastic support of BNYM and Newton who enabled equality to come to the Boat Races in 2015. CRUK's approach to scientific progress and medical breakthroughs is an inspiration to us. We are proud to be supported by them and hope that we can support the work they do as much as we can.”
CRUK and Cambridge have close links - The Cancer Research UK Cambridge Institute (CRUK-CI), at the Cambridge Biomedical Campus, aims to bring the scientific strengths of Cambridge to bear on practical questions of cancer diagnosis, treatment and prevention.
Curtis Arledge, Vice Chairman of BNY Mellon and CEO of Investment Management, commented: “We are committed to ensuring our sponsorship of The Boat Races reflects our focus on meaningful investments, especially when we can leverage our sponsorship to further effect change. We are proud to be working with CRUK, whose work touches the lives of so many.”
David Searle, Executive Director of The Boat Race Company Ltd said: “In BNY Mellon and Newton Investment Management we knew we had sponsors who would do something out of the ordinary. After making history with the introduction of The Women's Boat Race to the Tideway in 2015, this amazing gesture is breaking new ground in sponsorship.
Sir Harpal S. Kumar, Chief Executive of Cancer Research UK, said: “We are enormously grateful to BNY Mellon and Newton Investment Management for their generous donation. Cancer Research UK’s work has fuelled the progress that has seen cancer survival rates double in the last 40 years. Today, two in four people survive cancer. Our ambition is to accelerate progress so that three in four people survive cancer by 2034 and this donation is a very welcome contribution to that aim.”
Earlier this month, Cancer Research UK launched The Great Row – a new fitness challenge, which is completed on indoor rowing machines and encourages the nation to dust off their trainers and take part to help beat cancer sooner. To take part in The Great Row, individuals and teams can choose from different challenge levels; with rowing distances starting from 2,000metres, going up to a full marathon. Participants can train for free at Fitness First gyms every Friday throughout January, February and March, with The Great Row's official fitness partner welcoming participants every day from 19th – 26th March to complete their challenge ahead of the official races.
The Cancer Research UK Boat Races will take place on Sunday 27th March 2016. The Cancer Research UK Women's Boat Race will take place at 3.10pm GMT and The Cancer Research UK Boat Race at 4.10pm GMT.
More information:
About The Boat Races
The Boat Race is a major London event which takes place on the River Thames over 4¼ miles between Putney and Mortlake in the University Easter holidays. The first Race took place in 1829 and it has been held every year since 1856 with the exception of the two World Wars. The current score between the two men’s Clubs is Cambridge 81, Oxford 79 with one dead heat.
The first Women’s Boat Race took place in 1927 in the form of a time and style contest. Since then, the Oxford and Cambridge University Women’s Boat Clubs have competed annually. In 2015, following a decision by The Boat Race Company Ltd and with the invaluable help of BNY Mellon and Newton Investment Management, it relocated to The Championship Course from Putney to Mortlake to compete on the same day as the men across the same course. The current score between the two women’s Clubs is Cambridge 41, Oxford 29.
About Cancer Research UK
Cancer Research UK was announced as the official charity partner of The Boat Races in October 2015
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
Today, two in four people survive cancer. Cancer Research UK’s ambition is to accelerate progress so that three in four people will survive cancer within the next 20 years.
Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured
Newton Investment Management is a London-based global investment management subsidiary of The Bank of New York Mellon Corporation. With assets under management of £45.2 billion (as at September 30, 2015), including assets managed by Newton Investment Management Limited as dual officers of Newton Capital Management Limited and The Bank of New York Mellon, Newton's group of affiliated companies provides investment products and services to a wide range of clients, including pension funds, charities, corporations and (via BNY Mellon) individuals. News and other information about Newton are available at www.newton.co.uk and via Twitter: @NewtonIM.
BNY Mellon Investment Management is one of the world's leading investment management organisations and one of the top US wealth managers, with $1.6 trillion in assets under management. It encompasses BNY Mellon’s affiliated investment management firms, wealth management services and global distribution companies. More information can be found at www.bnymellon.com.
BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. Whether providing financial services for institutions, corporations or individual investors, BNY Mellon delivers informed investment management and investment services in 35 countries and more than 100 markets. As of September 30, 2015, BNY Mellon had $28.5 trillion in assets under custody and/or administration, and $1.6 trillion in assets under management. BNY Mellon can act as a single
point of contact for clients looking to create, trade, hold, manage, service, distribute or restructure investments. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK). Additional information is available on www.bnymellon.com. Follow us on Twitter @BNYMellon or visit our newsroom at www.bnymellon.com/newsroom for the latest company news.
The text in this work is licensed under a Creative Commons Attribution 4.0 International License. For image use please see separate credits above.